Topotecan: A New Topoisomerase I Inhibiting Antineoplastic Agent-Reference-Cited by-同舟云学术

Topotecan: A New Topoisomerase I Inhibiting Antineoplastic Agent

Published:1998-12 Issue:12 Volume:32 Page:1334-1343
ISSN:1060-0280
Container-title:Annals of Pharmacotherapy
language:en
Short-container-title:Ann Pharmacother

Author:

Cersosimo Robert J¹

Affiliation:

1. Robert J Cersosimo PharmD, Associate Professor of Clinical Pharmacy, Bouvé College of Pharmacy & Health Sciences, Northeastern University; Consultant Pharmacist, Department of Hematology/Medical Oncology, Veterans Administration Medical Center, Boston, MA

Publisher

SAGE Publications

Subject

Pharmacology (medical)

Link

http://journals.sagepub.com/doi/pdf/10.1345/aph.18049

Reference85 articles.

1. Molecular, cellular, and clinical aspects of the pharmacology of 20(S)camptothecin and its derivatives

2. Clinical Pharmacokinetics of Topotecan

3. Phase I Clinical and Pharmacology Study of Topotecan Given Daily for 5 Consecutive Days to Patients With Advanced Solid Tumors, With Attempt at Dose Intensification Using Recombinant Granulocyte Colony-Stimulating Factor

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Toward precision medicine in glioblastoma: the promise and the challenges;Neuro-Oncology;2015-05-01

2. Optimal Management of Ewing Sarcoma Family of Tumors: Recent Developments in Systemic Therapy;Pediatric Drugs;2013-06-13

3. High Antimetastatic Efficacy of MEN4901/T-0128, a Novel Camptothecin Carboxymethyldextran Conjugate;Journal of Surgical Research;2011-12

4. A Phase II Clinical Trial of Topotecan in Japanese Patients with Relapsed Ovarian Carcinoma;Japanese Journal of Clinical Oncology;2010-10-25

5. Treatment of Rat Brain Tumors Using Sustained-Release of Camptothecin from Poly(lactic-co-glycolic acid) Microspheres in a Thermoreversible Hydrogel;Chemical and Pharmaceutical Bulletin;2010